UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2011
Commission File Number 001-32374
SYMMETRY MEDICAL INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 35-1996126 | |
| (State of Incorporation) |
(I.R.S. Employer Identification No.) |
3724 North State Road 15
Warsaw, Indiana 46582
(Address of Principal Executive Offices) (Zip Code)
(574) 268-2252
(Registrant's Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class: | Name of Each Exchange on Which Registered: | |
| Common Stock, Par Value $0.001 Per Share | New York Stock Exchange |
Securities registered pursuant to section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes o No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes o No x
Indicate by check mark whether the registrant (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes x No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and" smaller reporting company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer o | Accelerated filer x | Non-accelerated filer o | Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes o No x
The aggregate market value of voting stock of Symmetry Medical Inc. held by non-affiliates of the Registrant as of July 2, 2011, based on the closing price was $9.26, as reported by the New York Stock Exchange: Approximately $336.0 million.
The number of outstanding shares of the registrant's common stock as of March 12, 2012 was 36,575,331.
EXPLANATORY NOTE
This Form 10-K/A is being filed to correct a typographical error on the cover page of the original Form 10-K. The actual number of outstanding shares of the registrant's common stock as of March 12, 2012 was 36,575,331. As a result of a typographical error, the original Form 10-K erroneously listed this figure as 35,575,331. No other changes to the disclosure in the original Form 10-K are made by this Form 10-K/A.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SYMMETRY MEDICAL INC. | ||
| April 16, 2012 |
By: /s/ Thomas J. Sullivan Thomas J. Sullivan Chief Executive Officer and President | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the date indicated.
| Name | Title | Date | ||
|
/s/ Thomas J. Sullivan Thomas J. Sullivan |
Chief Executive Officer, President and Director (Principal Executive Officer) |
April 16, 2012 | ||
|
/s/ Fred L. Hite Fred L. Hite |
Senior Vice President,
Chief Financial Officer and Secretary |
April 16, 2012 | ||
|
/s/ Ronda L. Harris Ronda L. Harris |
Chief Accounting Officer |
April 16, 2012 | ||
|
* Craig B. Reynolds |
Director |
April 16, 2012 | ||
|
* Francis T. Nusspickel |
Director |
April 16, 2012 | ||
|
* James S. Burns |
Director |
April 16, 2012 | ||
|
* John S. Krelle |
Director |
April 16, 2012 | ||
|
* Thomas E. Chorman |
Director |
April 16, 2012 | ||
|
* Robert G. Deuster |
Director |
April 16, 2012 | ||
|
*By: /s/ Fred L. Hite Fred L. Hite Attorney-in-fact Pursuant to Power of Attorney (Exhibit 24.1 hereto) |